Skip to main content
  • Home
  •  The Advancing Management of Transthyretin Amyloidosis: A Practical Guide

The Advancing Management of Transthyretin Amyloidosis: A Practical Guide

Topic:
  • Heart Failure

Available Credit:

  • 1.00 EBAC

Course Published On:

Course Expiry Date:

No ratings

Overview

Radcliffe Medical Education bring together a globally-renowned faculty, including Prof Julian Gillmore (University College London, London, UK) as he chairs a panel of distinguished experts, Dr Martha Grogan (Mayo Clinic College of Medicine, US), Dr Laura Obici (I.R.C.C.S. San Matteo Polyclinic, IT) and Prof Arnt Kristen (University of Heidelberg, Heidelberg, DE) in this interactive symposium covering the unique challenges of ATTR in diagnosis, assessment, long-term management and future treatment options.
 

During this session, the panel discuss key aspects related to ATTR-cm including the need for standardised and coordinated care, identifying disease progression and assessing quality of life after initiating treatment.

Support Statement

This Satellite Symposium was supported by an unrestricted educational grant from AstraZeneca who has no involvement in the content.

Disclosure

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
 

The session, ‘Individualising Antithrombotic Strategies for Established Coronary Artery Disease’ is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 hour of external CME credits. 
 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionalsand the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

Instruction to Participants

There is no fee for taking part in this online learning activity.
 

Activities are designed to be completed within 90 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
 

To complete the course and claim certification participants must:
 

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.

Target Audience

  • Heart Failure Specialist
  • Echocardiologist
  • Cardiac Amyloidosis Specialist

Learning Objectives

  • To differentiate ATTR phenotypes based on presenting signs and symptoms.
  • To select appropriate tests to monitor symptomatic ATTR-cm from imaging, biomarker, functional and QoL assessments.
  • To recall how to identify disease progression across ATTR-cm.
  • To describe the different disease modifying treatments for ATTR including novel agents.
Register now Log in

Module

Title

Duration

Speakers

Session 1 ATTR – A Multi-system Disease Posing Unique Challenges 11m 43s Julian Gillmore (Amsterdam, NL)
Session 2 Assessing Cardiac Manifestations of ATTR 16:57 Martha Grogan (Amsterdam, NL)
Session 3 Long-term Management 15m 23s Laura Obici (Amsterdam, NL)
Session 4 What’s in our Future Toolbox? 8m 47s Arnt Kristen (Amsterdam, NL)
Session 5 Meeting Summary and Conclusions 2m 11s Julian Gillmore (Amsterdam, NL) Martha Grogan (Amsterdam, NL) Arnt Kristen (Amsterdam, NL) Laura Obici (Amsterdam, NL)
Session 1.

ATTR – A Multi-system Disease Posing Unique Challenges

Duration: 11m 43s

Speakers: Julian Gillmore (Amsterdam, NL)

Session 2.

Assessing Cardiac Manifestations of ATTR

Duration: 16:57

Speakers: Martha Grogan (Amsterdam, NL)

Session 3.

Long-term Management

Duration: 15m 23s

Speakers: Laura Obici (Amsterdam, NL)

Session 4.

What’s in our Future Toolbox?

Duration: 8m 47s

Speakers: Arnt Kristen (Amsterdam, NL)

Course Director

Julian Gillmore

University College London, London, UK

Julian Gillmore gained his medical degree at University of London. He trained in nephrology and undertook MD and PhD degrees in the field of amyloidosis. His research interests include pathogenesis, diagnosis and treatment of amyloidosis.

View full profile

Speaker

Martha Grogan

Dr Martha Grogan, is a Former Chief of Internal Medicine and Medical Director, Assistant Warden, at the Federal Medical Center while fulfilling a National Health Service Corps commitment.

View full profile

Speaker

Arnt Kristen

University of Heidelberg, Heidelberg, DE

Arnt Kristen practices in Heidelberg, Germany. His top areas of expertise are Primary Amyloidosis, Transthyretin Amyloidosis, Cardiac Amyloidosis, Heart Transplant, and Tissue Biopsy.

View full profile

Speaker

Laura Obici

I.R.C.C.S. San Matteo Polyclinic, Pavia, IT

Laura Obici practices in Pavia, Italy. Dr Obici and is regarded in 16 conditions. Her top areas of expertise are Transthyretin Amyloidosis, Primary Amyloidosis, Familial Transthyretin Amyloidosis, Cardiac Amyloidosis, and Tissue Biopsy.

View full profile
1.00 EBAC

 The Advancing Management of Transthyretin Amyloidosis: A Practical Guide's programme has been accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1 CME point, equating to 1 hour of learning. Physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™.

Related Courses

A Race Against Time: Accelerating the Adoption of GDMT in Heart Failure
  • Not accredited

Learning objectives

  • Recall guideline recommendations for the use of NT-proBNP in heart failure
  • Describe current practices in heart failure diagnosis and the impact on treatment outcomes
  • Develop an optimised approach to the timely diagnosis and management of heart failure
See more
Implementing Heart Failure Guidelines with Collaborative Care
  • Not accredited

Learning objectives

  • Appraise new updates in heart failure guideline-directed medical therapy (GDMT)
  • Apply latest guideline recommendations to patient cases
  • Describe barriers preventing early initiation of GDMT
  • Identify the roles of nurses and other healthcare professionals to achieve optimal heart failure therapy
  • Identify the importance of the nurse/cross-functional team
See more
Overcoming the Challenges in Optimising GDMT in HF
  • Not accredited

Learning objectives

  • Appraise the urgency needed in rapid initiation of GDMT to improve HF outcomes.
  • Recognise barriers preventing the use of GDMT in current practice.
  • Identify strategies needed to drive implementation of GDMT in clinical practice.
See more
Hyperkalaemia in Cardiorenal Disease – A Case Based Discussion
  • Not accredited

Learning objectives

  • Explain the relationship between sub-optimal RAASi therapy and poor cardio-renal outcomes
  • Identify patients who would benefit from anti-hyperkalaemia medications
  • Select appropriate anti-hyperkalaemia treatments across a range of patient profiles
  • Adopt anti-hyperkalaemia medications as an approach to prolong optimal RAASi therapy
  • Summarise current guideline recommendations on the use of potassium binding agents
See more
Examining a Complex Heart Failure Case
  • 1.00 EBAC

Learning objectives

  • Identify individuals likely to have HFpEF from initial presentation
  • Refer suspected individuals for specialist assessment
  • Initiate GDMT for HF as soon as patients are stable 
  • Initiate GDMT in HF regardless of EF and phenotype
  • Initiate shared decision-making on complex HF patients with other members of the multidisciplinary team including cardiologists, GPs, nephrologists and diabetologists
See more
Obstructive Hypertrophic Cardiomyopathy: Getting It Right First Time
  • 1.00 EBAC

Learning objectives

  • Recall the general approach to diagnosis and stratification of HCM according to the latest guidelines and expert opinion
  • Apply advanced echocardiographic methodologies to equivocal HCM diagnoses
  • Select appropriate imaging modalities to facilitate accurate risk stratification
  • Stratify patients based on specific risk features and disease severity
  • Choose suitable treatment modalities for patients based on specific disease features and severity
See more
Incorporating GDMT and PRO Endpoints for Personalised HF Management
  • 1.00 EBAC

Learning objectives

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients
See more
Changing Paradigms in Therapy to Unmet Needs
  • 1.00 EBAC

Learning objectives

  • Recall the utility of EF in heart failure treatment, patient selection and treatment response 
  • Identify alternative measures to EF for the purposes HF severity and therapeutic efficacy 
  • Incorporate quality of life measures for assessing therapeutic efficacy in HF 
  • Recall outcomes from heart failure trials from recent congress and publications and their impact on practice 
See more
SGLT-2 Inhibitors - Another Piece of the Puzzle in Heart Failure
  • 1.00 EBAC

Learning objectives

  • Recall the results of key trials in HFmrEF in different patients' sub-groups
  • Describe how SGLT-2 inhibitors can be used across the range of LVEF
  • Apply emerging diagnostic approaches for HFpEF and HFmrEF
  • Implement best-practice strategies across the range of LVEF
See more
Making Gains in HFpEF: An Appraisal of Where We Are Now
  • Not accredited

Learning objectives

  • Identify HFpEF patients who may benefit from being initiated on an SGLT-2 inhibitor
  • Recall current inertia rates amongst prescribers who manage heart failure
  • Adopt effective treatment strategies for HFpEF patients early in the disease course
  • Recall current guideline directed medical therapy options in HFpEF
  • Review clinical, real world and quality of life evidence for the use of SGLT-2 inhibitors in HFpEF
See more